Part 3/9:
A startup called Insilico Medicine has pioneered the use of generative AI to develop new drugs, cutting down traditional development times and costs. Their AI algorithms can identify possible drug targets and design new drug molecules efficiently. With a recent IPF drug currently in phase two clinical trials, the efficiency of AI in drug development indicates a potential for significant advancements in areas once deemed hopeless.